Symptoms and General Pathology

All Conditions

Blood and Lymph Conditions

Neoplasms

Heart and Blood Diseases

Rare Diseases

Philadelphia Chromosome

Myeloproliferative Disorders

Polycythemia Vera

Polycythemia

Primary Myelofibrosis

Thrombocytosis

Thrombocythemia, Essential

Bone Marrow Diseases

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Translocation, Genetic

Chromosome Aberrations

Chronic Myeloproliferative Disorders

Essential Thrombocythemia

Rona S Weinberg, PhD

John Mascarenhas, MD

Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation.

The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.

Leftover tissue will be asked for to be stored in the MPD-RC Tissue Bank

Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD

Myeloproliferative Disorders-Research Consortium

National Cancer Institute (NCI)

Icahn School of Medicine at Mount Sinai

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Correlative Biomarker Study in Patients With Myeloproliferative Disorders	NCT00665067	Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve...		18 Years -	Icahn School of Medicine at Mount Sinai
Correlative Biomarker Study in Patients With Myeloproliferative Disorders	NCT00665067	Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve...		18 Years -	Icahn School of Medicine at Mount Sinai

Spots Global Cancer Trial Database for clonal hematopoietic malignancies